

**RETRACTION NOTE**

# Retraction Note to: FOXC2 promotes colorectal cancer metastasis by directly targeting MET

Y-M Cui, H-L Jiao, Y-P Ye, C-M Chen, J-X Wang, N. Tang, T-T Li, J. Lin, L. Qi, P. Wu, S-Y Wang, M-R He, L. Liang, X-W Bian, W-T Liao and Y-Q Ding

© The Author(s), under exclusive licence to Springer Nature Limited 2022

*Oncogene* (2022) 41:2529; <https://doi.org/10.1038/s41388-022-02287-w>

Retraction to: *Oncogene* <https://doi.org/10.1038/onc.2014.368>, published online 10 November 2014

The Editor-in-Chief has retracted this article. After publication, duplicated western blot bands were identified in Figs. 3 and 4 ( $\alpha$ -tubulin), as well as between Figs. 2a, 6b and 7a in this article and images previously published in [1] that represent different treatment groups. The Editor-in-Chief therefore no longer has confidence in the presented data.

Authors Y-M Cui, H-L Jiao, C-M Chen, L Qi, X-W Bian, W-T Liao and Y-Q Ding agree to this retraction. Authors Y-P Ye, J-X Wang, N

Tang, T-T Li, J Lin, P Wu, S-Y Wang, M-R He and L Liang have not responded to any correspondence from the editor or publisher about this retraction.

**REFERENCE**

1. Cui Y-M, et al. FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways. *Cancer Lett.* 2014;353.1:87–94. <https://doi.org/10.1016/j.canlet.2014.07.008>